Novo Nordisk A/S buy boersenhaendler
Summary
This prediction ended on 20.07.11 with a price of €17.87. With a performance of 8.62%, the BUY prediction by boersenhaendler for Novo Nordisk A/S closed with a slight gain. boersenhaendler has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | 1.776% | 3.175% | 14.882% | 17.660% |
iShares Nasdaq 100 | -1.037% | 1.869% | 35.463% | 52.324% |
iShares Nikkei 225® | -0.335% | 3.857% | 14.485% | 11.459% |
iShares S&P 500 | 0.854% | 2.567% | 31.105% | 47.441% |
Comments by boersenhaendler for this prediction
In the thread Novo Nordisk A/S diskutieren
Rebound
Ich gehe von einen weiteren Wachstum aus und denke daher das wir für die Zukunft steigende Kurse hier haben werden. Mal schauen wie weit es geht.